Eli Lilly and Company (LLY) Stock Analysis — Probabli.AI
AI-powered analysis for LLY (Eli Lilly and Company): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment.
← Healthcare Stocks
Last price: $1,288.30 · Market cap: $1.15T
Eli Lilly stands as the preeminent mega-cap pharmaceutical growth engine, propelled by historic demand for its dual GIP/GLP-1 receptor agonist portfolio (Mounjaro and Zepbound) and superior commercial execution reflected in 8 consecutive quarters of earnings beats. With projected top-line growth exceeding 27% and a fortified pipeline featuring oral candidate orforglipron and triple agonist…
Probabilistic 1-Year Outlook
- Bull 65% · Neutral 25% · Bear 10%
- 1-year price estimates — P10: $1,120 / P50: $1,520 / P90: $1,800
- Robust top-line growth of ~28%, driven by unyielding demand for tirzepatide (Mounjaro and Zepbound), an 8-quarter earnings beat streak, and expanding manufacturing capacity that continues to alleviate historical supply…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $1,700 / P50: $2,750 / P90: $3,850
SWOT Highlights
- Strength: Industry-leading incretin/GLP-1 franchise (Mounjaro/Zepbound) demonstrating best-in-class efficacy profiles
- Strength: Exceptional financial execution marked by 8 consecutive earnings beats and high net margins
- Risk: High revenue concentration and short-to-medium term valuation dependence on tirzepatide
- Risk: Premium valuation multiples (high forward P/E) leave thin margin for clinical or supply setbacks
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
31 Wall Street analysts rate LLY a BUY with a mean price target of $1,381.82. Eli Lilly and Company currently pays a dividend with a yield of approximately 0.54%.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
LLY forecast details · LLY sentiment details · LLY insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Eli Lilly and Company (LLY) — saved
Eli Lilly stands as the preeminent mega-cap pharmaceutical growth engine, propelled by historic demand for its dual GIP/GLP-1 receptor agonist portfolio (Mounjaro and Zepbound) and superior commercial execution reflected in 8 consecutive qu
- Eli Lilly and Company (LLY) — saved
Eli Lilly demonstrates strong fundamentals, underscored by consistent earnings beats, a robust pipeline, and strategic market expansions. While recognizing potential risks, these strengths position it well for above-average growth.
- Eli Lilly and Company (LLY) — saved
Eli Lilly & Company showcases exceptional growth potential, backed by a robust drug pipeline, strong financial fundamentals, and analysts' consensus support. Its focus on innovative therapeutic areas presents considerable upside over the me
- Eli Lilly and Company (LLY) — saved
Eli Lilly maintains a strong growth outlook fueled by innovation in high-demand therapeutic areas such as diabetes and Alzheimer's. The company is heavily investing in R&D and expanding its global footprint, aligning with bullish investor s
- Eli Lilly and Company (LLY) — saved
Eli Lilly is strategically positioned for continued success, driven by its innovative drug pipeline, favorable analyst views, consistent earnings performance, and effective expansion in diabetes management technologies. Despite potential he
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.